CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive increase in pulmonary vascular resistance (PVR), higher pulmonary arteries mean pressure (mPAP), decrease in cardiac minute output (CMO) and other hemodynamic, functional and biochemical disorders. Exist...

ver descrição completa

Detalhes bibliográficos

Principais autores:	E. A. Devetyarova, A. A. Dyuzhikov, A. A. Dyuzhikova, S. V. Sobin, A. V. Sumin, E. V. Pashchenko
Formato:	Artigo
Idioma:	Russo
Publicado em:	InterMedservice 2018-06-01
Colecção:	Евразийский Кардиологический Журнал
Assuntos:	pulmonary hypertension pulmonary arterial hypertension riociguat bosentan therapy
Acesso em linha:	https://www.heartj.asia/jour/article/view/287
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!